JP2022537047A5 - - Google Patents

Info

Publication number
JP2022537047A5
JP2022537047A5 JP2021575482A JP2021575482A JP2022537047A5 JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
administration
acceptable salt
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021575482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537047A (ja
JP7628512B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/055653 external-priority patent/WO2020254985A1/en
Publication of JP2022537047A publication Critical patent/JP2022537047A/ja
Publication of JP2022537047A5 publication Critical patent/JP2022537047A5/ja
Application granted granted Critical
Publication of JP7628512B2 publication Critical patent/JP7628512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021575482A 2019-06-19 2020-06-17 ヒト免疫不全ウイルス複製の阻害剤としてのピリド[2,3-d]ピリミジン誘導体 Active JP7628512B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022537047A JP2022537047A (ja) 2022-08-23
JP2022537047A5 true JP2022537047A5 (cg-RX-API-DMAC7.html) 2023-06-21
JP7628512B2 JP7628512B2 (ja) 2025-02-10

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575482A Active JP7628512B2 (ja) 2019-06-19 2020-06-17 ヒト免疫不全ウイルス複製の阻害剤としてのピリド[2,3-d]ピリミジン誘導体

Country Status (33)

Country Link
US (2) US12129255B2 (cg-RX-API-DMAC7.html)
EP (1) EP3986561B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102932817B1 (cg-RX-API-DMAC7.html)
CN (2) CN114245795B (cg-RX-API-DMAC7.html)
AR (1) AR119174A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020295793B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021025655A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021003388A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017479A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210664A (cg-RX-API-DMAC7.html)
DK (1) DK3986561T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974541T3 (cg-RX-API-DMAC7.html)
FI (1) FI3986561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240501T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065762T2 (cg-RX-API-DMAC7.html)
IL (1) IL288750B2 (cg-RX-API-DMAC7.html)
LT (1) LT3986561T (cg-RX-API-DMAC7.html)
MA (1) MA56526B1 (cg-RX-API-DMAC7.html)
MD (1) MD3986561T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021016149A (cg-RX-API-DMAC7.html)
MY (1) MY206712A (cg-RX-API-DMAC7.html)
PE (1) PE20220510A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553180A1 (cg-RX-API-DMAC7.html)
PL (1) PL3986561T3 (cg-RX-API-DMAC7.html)
PT (1) PT3986561T (cg-RX-API-DMAC7.html)
RS (1) RS65304B1 (cg-RX-API-DMAC7.html)
SI (1) SI3986561T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400153T1 (cg-RX-API-DMAC7.html)
TW (1) TWI850403B (cg-RX-API-DMAC7.html)
UA (1) UA128967C2 (cg-RX-API-DMAC7.html)
UY (1) UY38755A (cg-RX-API-DMAC7.html)
WO (1) WO2020254985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
US12415771B2 (en) 2019-06-19 2025-09-16 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
AU2020358156B2 (en) * 2019-10-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Method for treating HIV with cabotegravir and rilpivirine
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364279A1 (en) 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2022531251A5 (cg-RX-API-DMAC7.html)
JP7330312B2 (ja) Hivを治療するためのトール様受容体の調節因子
HRP20240501T1 (hr) Derivati pirido[2,3-d]pirimidina kao inhibitori replikacije virusa humane imunodeficijencije
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2022191257A5 (cg-RX-API-DMAC7.html)
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2021100937A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2022523726A5 (cg-RX-API-DMAC7.html)
JP2018188483A5 (cg-RX-API-DMAC7.html)
JP2009535352A5 (cg-RX-API-DMAC7.html)
JP2022525013A5 (cg-RX-API-DMAC7.html)
JP2024512425A5 (cg-RX-API-DMAC7.html)
JP2016516773A5 (cg-RX-API-DMAC7.html)
JP2017533220A5 (cg-RX-API-DMAC7.html)
JP2024520132A5 (cg-RX-API-DMAC7.html)
JP2025508656A5 (cg-RX-API-DMAC7.html)
JP2023537921A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2020536098A5 (cg-RX-API-DMAC7.html)
RU2019139864A (ru) Санфетринем или его соль или сложный эфир для применения при лечении микобактериальной инфекции
JP2002533470A5 (cg-RX-API-DMAC7.html)
JP2005507944A5 (cg-RX-API-DMAC7.html)
US11191763B2 (en) HIV post-exposure prophylaxis
JP2022533011A5 (cg-RX-API-DMAC7.html)